Literature DB >> 1271013

Successful treatment of enterovirus-infected mice by 2-(alpha-hydroxybenzyl)-benzimidazole and guanidine.

H J Eggers.   

Abstract

Echo virus 9- or Coxsackie A 9-infected newborn mice are protected from paralysis and death by combined treatment with nontoxic concentrations of HBB plus guanidine. HBB alone also protects Coxsackie A 9, but not echo virus 9-infected animals, whereas guanidine alone is ineffective in either case. Protection is due to inhibition of virus multiplication via the antiviral activity of these selective inhibitors. Treatment must be begun at the latest 48 h after virus inoculation. 3 days of treatment are sufficient if started at the time of virus inoculation. Failure of protection after treatment with one compound alone is not due to rapid development of drug-resistant virus mutants. Infected, successfully treated mice may develop a solid immunity.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1271013      PMCID: PMC2190224          DOI: 10.1084/jem.143.6.1367

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  15 in total

1.  ANTIVIRAL ACTIVITY OF SELECTED BENZIMIDAZOLES.

Authors:  G M FARA; K W COCHRAN
Journal:  Boll Ist Sieroter Milan       Date:  1963 Nov-Dec

2.  STUDIES ON THE MECHANISM OF POLIOVIRUS-INDUCED CELL DAMAGE. I. THE RELATION BETWEEN POLIOVIRUS,-INDUCED METABOLIC AND MORPHOLOGICAL ALTERATIONS IN CULTURED CELLS.

Authors:  R BABLANIAN; H J EGGERS; I TAMM
Journal:  Virology       Date:  1965-05       Impact factor: 3.616

3.  Heterogeneity of Coxsackie B4 virus: two kinds of particles which differ in antibody sensitivity, growth rate, and plaque size.

Authors:  P W CHOPPIN; H J EGGERS
Journal:  Virology       Date:  1962-11       Impact factor: 3.616

4.  Differences in the selective virus inhibitory action of 2-(alpha-hydroxybenzyl)-benzimidazole and guanidine HCl.

Authors:  I TAMM; H J EGGERS
Journal:  Virology       Date:  1962-11       Impact factor: 3.616

5.  Rapid development of drug-resistant mutants of poliovirus.

Authors:  J L MELNICK; D CROWTHER; J BARRERA-ORO
Journal:  Science       Date:  1961-08-25       Impact factor: 47.728

6.  Effects of certain purines and related compounds on virus propagation.

Authors:  A C HOLLINSHEAD; P K SMITH
Journal:  J Pharmacol Exp Ther       Date:  1958-05       Impact factor: 4.030

7.  Protective action of benzimidazole derivatives against virus infections in tissue culture and in vivo.

Authors:  D G O'Sullivan; D Pantic; D S Dane; M Briggs
Journal:  Lancet       Date:  1969-03-01       Impact factor: 79.321

Review 8.  Antiviral chemotherapy.

Authors:  H J Eggers; I Tamm
Journal:  Annu Rev Pharmacol       Date:  1966       Impact factor: 13.820

9.  2,(alpha-hydroxybenzyl)-benzimidazole (HBB) as an aid in virus classification.

Authors:  H J EGGERS; I TAMM
Journal:  Virology       Date:  1961-04       Impact factor: 3.616

10.  Spectrum and characteristics of the virus inhibitory action of 2-(alpha-hydroxybenzyl)-benzimidazole.

Authors:  H J EGGERS; I TAMM
Journal:  J Exp Med       Date:  1961-04-01       Impact factor: 14.307

View more
  10 in total

1.  Evaluation of antiviral therapies in respiratory and neurological disease models of Enterovirus D68 infection in mice.

Authors:  Brett L Hurst; W Joseph Evans; Donald F Smee; Arnaud J Van Wettere; E Bart Tarbet
Journal:  Virology       Date:  2018-10-31       Impact factor: 3.616

2.  Selective inhibition of human neutrophil chemotaxis by ECHO-virus, type 9.

Authors:  B Bültmann; H J Eggers; O Haferkamp
Journal:  Klin Wochenschr       Date:  1981-06-01

3.  An experimental study on the epidemiology of enteroviruses: water and soap washing of poliovirus 1--contaminated hands, its effectiveness and kinetics.

Authors:  W Schürmann; H J Eggers
Journal:  Med Microbiol Immunol       Date:  1985       Impact factor: 3.402

4.  Mutations in the 2C region of poliovirus responsible for altered sensitivity to benzimidazole derivatives.

Authors:  H Shimizu; M Agoh; Y Agoh; H Yoshida; K Yoshii; T Yoneyama; A Hagiwara; T Miyamura
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

5.  Susceptibilities of enterovirus D68, enterovirus 71, and rhinovirus 87 strains to various antiviral compounds.

Authors:  Donald F Smee; W Joseph Evans; K C Nicolaou; E Bart Tarbet; Craig W Day
Journal:  Antiviral Res       Date:  2016-04-07       Impact factor: 5.970

6.  The thiazolobenzimidazole TBZE-029 inhibits enterovirus replication by targeting a short region immediately downstream from motif C in the nonstructural protein 2C.

Authors:  Armando M De Palma; Ward Heggermont; Kjerstin Lanke; Bruno Coutard; Mirko Bergmann; Anna-Maria Monforte; Bruno Canard; Erik De Clercq; Alba Chimirri; Gerhard Pürstinger; Jacques Rohayem; Frank van Kuppeveld; Johan Neyts
Journal:  J Virol       Date:  2008-03-12       Impact factor: 5.103

7.  F-Met-Leu-Phe and echo 9 virus interaction with human granulocytes. Changes of cell membrane structure.

Authors:  B D Bültmann; P Allmendinger; R U Raus; I Melzner; O Haferkamp; H Eggers; H Gruler
Journal:  Am J Pathol       Date:  1984-07       Impact factor: 4.307

Review 8.  Picornavirus inhibitors.

Authors:  L Carrasco
Journal:  Pharmacol Ther       Date:  1994       Impact factor: 12.310

9.  Persistent viral infections as models for research in virus chemotherapy.

Authors:  G Streissle
Journal:  Adv Virus Res       Date:  1981       Impact factor: 9.937

Review 10.  Diagnosis of viral disease and the advent of antiviral drugs.

Authors:  E C Herrmann; J A Herrmann
Journal:  Pharmacol Ther       Date:  1979       Impact factor: 12.310

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.